Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction
- Autores
- Olea, Fernanda Daniela; De Lorenzi, Andrea; Cortés, Claudia; Cuniberti, Luis Alberto; Fazzi, Lucía; Flamenco, María del Pilar; Locatelli, Paola; Cabeza Meckert, Patricia; Bercovich, Andrés; Laguens, Rubén; Crottogini, Alberto José
- Año de publicación
- 2013
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- BACKGROUND: In reperfused acute myocardial infarction (RAMI), cardioprotective treatments may enhance myocardial salvage and hence reduce the area of necrosis. Based on studies showing that plasmid-mediated vascular endothelial growth factor (pVEGF) gene transfer reduces infarct size by combining angio-arteriogenic and cardiomyogenic effects and that erythropoietin (EPO) exerts anti-apoptotic actions in animal models of AMI, we aimed to assess if their association would reduce infarct size to a larger extent than any of them individually in a large mammalian model of RAMI. METHODS: Adult sheep subjected to 90-minute coronary artery occlusion received upon reperfusion intramyocardial pVEGF 3.8 mg plus intravenous EPO 1000 IU/kg (n=8), pVEGF (n=8), EPO (n=8) or placebo (n=8). RESULTS: Fifteen days after treatment, infarct size was smaller in the 3 treatment groups (pVEGF+EPO: 8 ± 1 %; pVEGF: 16 ± 5 %; EPO: 13 ± 4 %) compared to placebo (25 ± 7 %, p<0.001). However, in the EPO+VEGF group infarct size was significantly smaller than in the groups receiving EPO or VEGF individually (p<0.05). DNA fragmentation, a hallmark of late apoptosis, was significantly lower in sheep receiving EPO. The combined treatment, while not affecting global left ventricular performance, improved regional peri-infarct function and prevented over-time expansion of the post-infarct perfusion defect. CONCLUSIONS: Combined pVEGF and EPO treatment might be clinically useful to enhance the benefits of early revascularization in patients with acute myocardial infarction.
Fil: Olea, Fernanda Daniela. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: De Lorenzi, Andrea. Fundación Favaloro; Argentina
Fil: Cortés, Claudia. Fundación Favaloro; Argentina
Fil: Cuniberti, Luis Alberto. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Fazzi, Lucía. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Básicas de la Patología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Flamenco, María del Pilar. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina
Fil: Locatelli, Paola. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cabeza Meckert, Patricia. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Básicas de la Patología; Argentina
Fil: Bercovich, Andrés. Bio Sidus; Argentina
Fil: Laguens, Rubén. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Básicas de la Patología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Crottogini, Alberto José. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
Vegf
Erythropoietin
Reperfused Myocardial Infarction
Apoptosis
Sheep
Gene Therapy - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/24169
Ver los metadatos del registro completo
id |
CONICETDig_7c622a662964bb41a59b72776a37afd4 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/24169 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarctionOlea, Fernanda DanielaDe Lorenzi, AndreaCortés, ClaudiaCuniberti, Luis AlbertoFazzi, LucíaFlamenco, María del PilarLocatelli, PaolaCabeza Meckert, PatriciaBercovich, AndrésLaguens, RubénCrottogini, Alberto JoséVegfErythropoietinReperfused Myocardial InfarctionApoptosisSheepGene Therapyhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3BACKGROUND: In reperfused acute myocardial infarction (RAMI), cardioprotective treatments may enhance myocardial salvage and hence reduce the area of necrosis. Based on studies showing that plasmid-mediated vascular endothelial growth factor (pVEGF) gene transfer reduces infarct size by combining angio-arteriogenic and cardiomyogenic effects and that erythropoietin (EPO) exerts anti-apoptotic actions in animal models of AMI, we aimed to assess if their association would reduce infarct size to a larger extent than any of them individually in a large mammalian model of RAMI. METHODS: Adult sheep subjected to 90-minute coronary artery occlusion received upon reperfusion intramyocardial pVEGF 3.8 mg plus intravenous EPO 1000 IU/kg (n=8), pVEGF (n=8), EPO (n=8) or placebo (n=8). RESULTS: Fifteen days after treatment, infarct size was smaller in the 3 treatment groups (pVEGF+EPO: 8 ± 1 %; pVEGF: 16 ± 5 %; EPO: 13 ± 4 %) compared to placebo (25 ± 7 %, p<0.001). However, in the EPO+VEGF group infarct size was significantly smaller than in the groups receiving EPO or VEGF individually (p<0.05). DNA fragmentation, a hallmark of late apoptosis, was significantly lower in sheep receiving EPO. The combined treatment, while not affecting global left ventricular performance, improved regional peri-infarct function and prevented over-time expansion of the post-infarct perfusion defect. CONCLUSIONS: Combined pVEGF and EPO treatment might be clinically useful to enhance the benefits of early revascularization in patients with acute myocardial infarction.Fil: Olea, Fernanda Daniela. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: De Lorenzi, Andrea. Fundación Favaloro; ArgentinaFil: Cortés, Claudia. Fundación Favaloro; ArgentinaFil: Cuniberti, Luis Alberto. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Fazzi, Lucía. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Básicas de la Patología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Flamenco, María del Pilar. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas; ArgentinaFil: Locatelli, Paola. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Cabeza Meckert, Patricia. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Básicas de la Patología; ArgentinaFil: Bercovich, Andrés. Bio Sidus; ArgentinaFil: Laguens, Rubén. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Básicas de la Patología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Crottogini, Alberto José. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaElsevier Ireland2013-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/24169Olea, Fernanda Daniela; De Lorenzi, Andrea; Cortés, Claudia; Cuniberti, Luis Alberto; Fazzi, Lucía; et al.; Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction; Elsevier Ireland; International Journal of Cardiology; 165; 2; 5-2013; 291-2980167-5273CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0167527311009193info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ijcard.2011.08.078info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:37:32Zoai:ri.conicet.gov.ar:11336/24169instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:37:32.295CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction |
title |
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction |
spellingShingle |
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction Olea, Fernanda Daniela Vegf Erythropoietin Reperfused Myocardial Infarction Apoptosis Sheep Gene Therapy |
title_short |
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction |
title_full |
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction |
title_fullStr |
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction |
title_full_unstemmed |
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction |
title_sort |
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction |
dc.creator.none.fl_str_mv |
Olea, Fernanda Daniela De Lorenzi, Andrea Cortés, Claudia Cuniberti, Luis Alberto Fazzi, Lucía Flamenco, María del Pilar Locatelli, Paola Cabeza Meckert, Patricia Bercovich, Andrés Laguens, Rubén Crottogini, Alberto José |
author |
Olea, Fernanda Daniela |
author_facet |
Olea, Fernanda Daniela De Lorenzi, Andrea Cortés, Claudia Cuniberti, Luis Alberto Fazzi, Lucía Flamenco, María del Pilar Locatelli, Paola Cabeza Meckert, Patricia Bercovich, Andrés Laguens, Rubén Crottogini, Alberto José |
author_role |
author |
author2 |
De Lorenzi, Andrea Cortés, Claudia Cuniberti, Luis Alberto Fazzi, Lucía Flamenco, María del Pilar Locatelli, Paola Cabeza Meckert, Patricia Bercovich, Andrés Laguens, Rubén Crottogini, Alberto José |
author2_role |
author author author author author author author author author author |
dc.subject.none.fl_str_mv |
Vegf Erythropoietin Reperfused Myocardial Infarction Apoptosis Sheep Gene Therapy |
topic |
Vegf Erythropoietin Reperfused Myocardial Infarction Apoptosis Sheep Gene Therapy |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
BACKGROUND: In reperfused acute myocardial infarction (RAMI), cardioprotective treatments may enhance myocardial salvage and hence reduce the area of necrosis. Based on studies showing that plasmid-mediated vascular endothelial growth factor (pVEGF) gene transfer reduces infarct size by combining angio-arteriogenic and cardiomyogenic effects and that erythropoietin (EPO) exerts anti-apoptotic actions in animal models of AMI, we aimed to assess if their association would reduce infarct size to a larger extent than any of them individually in a large mammalian model of RAMI. METHODS: Adult sheep subjected to 90-minute coronary artery occlusion received upon reperfusion intramyocardial pVEGF 3.8 mg plus intravenous EPO 1000 IU/kg (n=8), pVEGF (n=8), EPO (n=8) or placebo (n=8). RESULTS: Fifteen days after treatment, infarct size was smaller in the 3 treatment groups (pVEGF+EPO: 8 ± 1 %; pVEGF: 16 ± 5 %; EPO: 13 ± 4 %) compared to placebo (25 ± 7 %, p<0.001). However, in the EPO+VEGF group infarct size was significantly smaller than in the groups receiving EPO or VEGF individually (p<0.05). DNA fragmentation, a hallmark of late apoptosis, was significantly lower in sheep receiving EPO. The combined treatment, while not affecting global left ventricular performance, improved regional peri-infarct function and prevented over-time expansion of the post-infarct perfusion defect. CONCLUSIONS: Combined pVEGF and EPO treatment might be clinically useful to enhance the benefits of early revascularization in patients with acute myocardial infarction. Fil: Olea, Fernanda Daniela. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: De Lorenzi, Andrea. Fundación Favaloro; Argentina Fil: Cortés, Claudia. Fundación Favaloro; Argentina Fil: Cuniberti, Luis Alberto. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Fazzi, Lucía. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Básicas de la Patología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Flamenco, María del Pilar. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina Fil: Locatelli, Paola. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Cabeza Meckert, Patricia. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Básicas de la Patología; Argentina Fil: Bercovich, Andrés. Bio Sidus; Argentina Fil: Laguens, Rubén. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Básicas de la Patología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Crottogini, Alberto José. Universidad Favaloro. Facultad de Medicina. Departamento de Ciencias Fisiológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
description |
BACKGROUND: In reperfused acute myocardial infarction (RAMI), cardioprotective treatments may enhance myocardial salvage and hence reduce the area of necrosis. Based on studies showing that plasmid-mediated vascular endothelial growth factor (pVEGF) gene transfer reduces infarct size by combining angio-arteriogenic and cardiomyogenic effects and that erythropoietin (EPO) exerts anti-apoptotic actions in animal models of AMI, we aimed to assess if their association would reduce infarct size to a larger extent than any of them individually in a large mammalian model of RAMI. METHODS: Adult sheep subjected to 90-minute coronary artery occlusion received upon reperfusion intramyocardial pVEGF 3.8 mg plus intravenous EPO 1000 IU/kg (n=8), pVEGF (n=8), EPO (n=8) or placebo (n=8). RESULTS: Fifteen days after treatment, infarct size was smaller in the 3 treatment groups (pVEGF+EPO: 8 ± 1 %; pVEGF: 16 ± 5 %; EPO: 13 ± 4 %) compared to placebo (25 ± 7 %, p<0.001). However, in the EPO+VEGF group infarct size was significantly smaller than in the groups receiving EPO or VEGF individually (p<0.05). DNA fragmentation, a hallmark of late apoptosis, was significantly lower in sheep receiving EPO. The combined treatment, while not affecting global left ventricular performance, improved regional peri-infarct function and prevented over-time expansion of the post-infarct perfusion defect. CONCLUSIONS: Combined pVEGF and EPO treatment might be clinically useful to enhance the benefits of early revascularization in patients with acute myocardial infarction. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-05 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/24169 Olea, Fernanda Daniela; De Lorenzi, Andrea; Cortés, Claudia; Cuniberti, Luis Alberto; Fazzi, Lucía; et al.; Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction; Elsevier Ireland; International Journal of Cardiology; 165; 2; 5-2013; 291-298 0167-5273 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/24169 |
identifier_str_mv |
Olea, Fernanda Daniela; De Lorenzi, Andrea; Cortés, Claudia; Cuniberti, Luis Alberto; Fazzi, Lucía; et al.; Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction; Elsevier Ireland; International Journal of Cardiology; 165; 2; 5-2013; 291-298 0167-5273 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0167527311009193 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ijcard.2011.08.078 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Ireland |
publisher.none.fl_str_mv |
Elsevier Ireland |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613182618861568 |
score |
13.070432 |